The combination of yunnan baiyao and Huawei may play a catalytic role in the domestic AI drug research and development field

Yesterday, Yunnan Baiyao issued an announcement that the company has signed a "Comprehensive Cooperation Agreement

Yesterday, Yunnan Baiyao issued an announcement that the company has signed a "Comprehensive Cooperation Agreement

The agreement stipulates that Huawei should leverage its advantages in ICT products and solutions, big data analytics, smart cities, and cloud computing to provide Yunnan Baiyao with competitive products and services, and assist Yunnan Baiyao in constructing and enhancing its industry-leading informatization capabilities

Some insiders said that the combination of yunnan baiyao and Huawei may play a certain catalytic role

AI Pharmaceuticals: AI Pharmaceuticals: AI Pharmaceuticals:

No products have been released to date

So far, no products have been listed, and no products have been listed so far

All along, long R&D cycle, high R&D input costs, and low success rates have been the "three mountains" in the field of new drug research

According to statistics, the use of AI technology can shorten the drug discovery time by 40%, save 50%-60% of the drug clinical trial time, and save tens of billions of dollars in compound screening costs and clinical trial costs

In the early years, foreign pharmaceutical giants have begun to cooperate with technology companies in AI drug research and development

However, it should be pointed out that there is not yet a drug that is mainly screened by AI methods and approved by the FDA to achieve marketing, but some AI pharmaceutical companies have obtained multiple compounds of PDCs that can be used for clinical trials through AI methods, or are close to the stage

According to a report by CCID Consultants, by the end of 2021, more than 40 AI-participating R&D pipelines around the world will enter the clinic
.
Among them, the pipelines of 8 foreign companies and 2 Chinese companies have entered the first phase of clinical practice, but due to the high difficulty of AI pharmaceutical technology, there are no drugs with AI prediction structure on the market
so far.
As of the end of April 2022, there are more than 60 AI pharmaceutical companies in China, and no company has yet been listed and profitable
.

According to a report by CCID Consultants, by the end of 2021, more than 40 AI-participating R&D pipelines around the world will enter the clinic
.
Among them, the pipelines of 8 foreign companies and 2 Chinese companies have entered the first phase of clinical practice, but due to the high difficulty of AI pharmaceutical technology, there are no drugs with AI prediction structure on the market
so far.
As of the end of April 2022, there are more than 60 AI pharmaceutical companies in China, and no company has yet been listed and profitable
.

The report predicts that by 2023-2025, a batch of AI-predicted drugs will enter the clinical phase II known as the "Valley of Death", and the first marketed AI pharmaceutical products
will appear in 2026-2027.

The report predicts that by 2023-2025, a batch of AI-predicted drugs will enter the clinical phase II known as the "Valley of Death", and the first marketed AI pharmaceutical products
will appear in 2026-2027.

Tech Giants:

Tech Giants: Tech Giants: Tech Giants:

Have laid out the AI pharmaceutical field

Have laid out the AI pharmaceutical field has laid out the AI pharmaceutical field has laid out the AI pharmaceutical field

As the leading player of domestic artificial intelligence technology, Huawei has long had a layout
in the AI-assisted drug research and development business.
In September last year, HUAWEI CLOUD released the "Pangu Drug Molecular Model", which belongs to the new member of the "Pangu Family", which is a pre-trained model specially launched for the field of drug research and development, aiming to help pharmaceutical companies open a new model
of AI-assisted drug development.

As the leading player of domestic artificial intelligence technology, Huawei has long had a layout
in the AI-assisted drug research and development business.
In September last year, HUAWEI CLOUD released the "Pangu Drug Molecular Model", which belongs to the new member of the "Pangu Family", which is a pre-trained model specially launched for the field of drug research and development, aiming to help pharmaceutical companies open a new model
of AI-assisted drug development.

In addition to the AI pharmaceutical field, Huawei also laid out the medical device field, and in august last year, in the name of the terminal company, it obtained the second class medical device registration certificate
.

In addition to the AI pharmaceutical field, Huawei also laid out the medical device field, and in august last year, in the name of the terminal company, it obtained the second class medical device registration certificate
.

Not only Huawei, in recent years, Tencent, Ali, Baidu and other Internet giants have also begun to set their sights on the field of AI new drug research and development after the layout of
Internet medical treatment.

Not only Huawei, in recent years, Tencent, Ali, Baidu and other Internet giants have also begun to set their sights on the field of AI new drug research and development after the layout of
Internet medical treatment.

Baidu founder Robin Li initiated the establishment of Baitu Shengke; Alibaba Cloud cooperates with Chia Tai Tianqing and global health drug research and development center GHDDI; Tencent released the AI-driven drug research and development platform "Yunshen Zhiyao"; ByteDance set up an Aurora department dedicated to the big health business and recruited AI-drug teams at home and abroad.
.
.

Baidu founder Robin Li initiated the establishment of Baitu Shengke; Alibaba Cloud cooperates with Chia Tai Tianqing and global health drug research and development center GHDDI; Tencent released the AI-driven drug research and development platform "Yunshen Zhiyao"; ByteDance set up an Aurora department dedicated to the big health business and recruited AI-drug teams at home and abroad.
.
.

According to data from the Internet Data Information Network (BCC), ai occupies the first place in all application scenarios of the medical and health industry, and the market size and growth rate of new drug discovery occupy the first place, and the market size is expected to reach 3.
117 billion US dollars in 2024, with an average annual compound growth rate (CAGR) of 40.
7%.

According to data from the Internet Data Information Network (BCC), ai occupies the first place in all application scenarios of the medical and health industry, and the market size and growth rate of new drug discovery occupy the first place, and the market size is expected to reach 3.
117 billion US dollars in 2024, with an average annual compound growth rate (CAGR) of 40.
7%.

According to the latest report from Grand View Research, the global AI+ drug discovery market size is expected to reach $3.
5 billion by 2027, with a CAGR of 28.
8%.

According to the latest report from Grand View Research, the global AI+ drug discovery market size is expected to reach $3.
5 billion by 2027, with a CAGR of 28.
8%.

Yunnan Baiyao:

Yunnan Baiyao: Yunnan Baiyao: Yunnan Baiyao:

He has twice introduced Huawei executives

Huawei executives have been introduced twice, Huawei executives have been introduced twice, and Huawei executives have been introduced twice

It is worth mentioning that in addition to the hand-in-hand with Huawei this time, Yunnan Baiyao has also hired two former executives of Huawei China to serve
in the company since last year.

It is worth mentioning that in addition to the hand-in-hand with Huawei this time, Yunnan Baiyao has also hired two former executives of Huawei China to serve
in the company since last year.

In March last year, Yunnan Baiyao hired Dong Ming as the company's chief executive officer
.
Dong Ming has more than 20 years of experience at Huawei, serving as a Huawei Technical Engineer, Director of Fixed Network Product Marketing in Huawei's Eastern Europe Region, and Vice President of Huawei China
.
In June this year, Dong Ming also nominated Ma Jia, former CFO of Huawei China, as the chief financial officer
of Yunnan Baiyao.

In March last year, Yunnan Baiyao hired Dong Ming as the company's chief executive officer
.
Dong Ming has more than 20 years of experience at Huawei, serving as a Huawei Technical Engineer, Director of Fixed Network Product Marketing in Huawei's Eastern Europe Region, and Vice President of Huawei China
.
In June this year, Dong Ming also nominated Ma Jia, former CFO of Huawei China, as the chief financial officer
of Yunnan Baiyao.

Yunnan Baiyao has successively introduced two Huawei executives, and now has carried out in-depth cooperation with Huawei, which may be related to the pressure on performance in recent years, and also "escort"
the company's digital transformation.

Yunnan Baiyao has successively introduced two Huawei executives, and now has carried out in-depth cooperation with Huawei, which may be related to the pressure on performance in recent years, and also "escort"
the company's digital transformation.

According to the 2021 annual report, the net profit attributable to the mother of Yunnan Baiyao was 2.
804 billion yuan, down 49.
17% year-on-year, which is the first decline in the net profit attributable to the mother of Yunnan Baiyao in
the past 20 years.
In the first quarter of 2022, Yunnan Baiyao's revenue also showed negative growth, with revenue of 9.
43 billion yuan, a year-on-year decrease of 8.
7%.

According to the 2021 annual report, the net profit attributable to the mother of Yunnan Baiyao was 2.
804 billion yuan, down 49.
17% year-on-year, which is the first decline in the net profit attributable to the mother of Yunnan Baiyao in
the past 20 years.
In the first quarter of 2022, Yunnan Baiyao's revenue also showed negative growth, with revenue of 9.
43 billion yuan, a year-on-year decrease of 8.
7%.

On March 28, 2021, Yunnan Baiyao said at an investor research conference that it would develop and transform
around the "1+4+1" strategy.
The first "1" refers to the development of deep ploughing in the field of traditional Chinese medicine; "4" refers to the oral field, the skin field, the bone injury field and the female care field; The last "1" refers to digital technology, Yunnan Baiyao will introduce new technologies including artificial intelligence into all aspects of research and development and operation, so that development has a higher starting point
.

On March 28, 2021, Yunnan Baiyao said at an investor research conference that it would develop and transform
around the "1+4+1" strategy.
The first "1" refers to the development of deep ploughing in the field of traditional Chinese medicine; "4" refers to the oral field, the skin field, the bone injury field and the female care field; The last "1" refers to digital technology, Yunnan Baiyao will introduce new technologies including artificial intelligence into all aspects of research and development and operation, so that development has a higher starting point
.

In addition, Yunnan Baiyao also said in the announcement that 2022 is a key year for the company's digital transformation and the implementation of medium- and long-term strategies, and it will invest in the oral business, skin management, medical beauty business and other sectors to create a foundation
for the company's second development curve.

In addition, Yunnan Baiyao also said in the announcement that 2022 is a key year for the company's digital transformation and the implementation of medium- and long-term strategies, and it will invest in the oral business, skin management, medical beauty business and other sectors to create a foundation
for the company's second development curve.